SLN

Silence Therapeutics plc

OTC · Pharmaceutical Preparations · Inc. X0 · CIK 0001479615

$6.03 +0.33% $281.3M

Vol

Market Cap$281.3M

Cap SizeMicro Cap

Inst. Holders3 funds

Inst. Value$2.2M

Inst. Activity0 buys / 2 sells

Insider Activity2B / 2S

SEC Reports1

Exchange OTC·Sector Pharmaceutical Preparations·Inc. X0·CIK 0001479615·Prev Close $6.01

Recent Activity

Jun 3, 2026 clinical_trial_readout

T-90d Trial Readout: SLN124 (Phase 2)

Trial: Study to Assess SLN124 in Patients With Polycythemia Vera Sponsor: Silence Therapeutics plc P

Mar 5, 2026 SEC

Silence Therapeutics reported a significant year-over-year decline in revenue and increased net loss, driven by the conc

8-K — Impact 6/10

Oct 27, 2025 Insider

Griffiths Richard Ian sold 2,000 shares

10%+ Owner @ $0.00 ($0.00)

Oct 27, 2025 Insider

Griffiths Richard Ian bought 2,000 shares

10%+ Owner @ $0.00 ($0.00)

Aug 3, 2025 Insider

Griffiths Richard Ian bought 20,000 shares

10%+ Owner @ $0.00 ($0.00)

Inst.

MORGAN STANLEY — TRIM

324,630 shares ($2.0M)

Inst.

TWO SIGMA INVESTMENTS, LP — TRIM

39,344 shares ($239.2K)

Price Targets

$31.20 +417.4% upside Strong Buy

Current $6.03 Low $4.00 Median $25.00 High $75.00 5 analysts

$4.00 $75.00

Analyst Ratings

Recent Analyst Actions

Date	Firm	Action	Rating
Mar 13, 2026	HC Wainwright & Co.	REITERATE	Buy → Buy

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-0.11 ▼ -10.0%	$-0.11 — $-0.11	80% YoY	1
Next Q	$-0.10	$-0.10 — $-0.10	33% YoY	1
Current FY	$-0.40 ▼ -2.6%	$-0.40 — $-0.40	78% YoY	1
Next FY	$-0.39	$-0.39 — $-0.39	3% YoY	1

Latest Reports

MIXED 8-K 6/10

Silence Therapeutics reported a significant year-over-year decline in revenue and increased net loss, driven by the conc

Mar 5, 2026

Top Institutional Holders

Fund	Value	Move
MORGAN STANLEY	$2.0M	TRIM
TWO SIGMA INVESTMENTS, LP	$239.2K	TRIM
BANK OF AMERICA CORP	$18.0K	TRIM

Recent Insider Trades

Date	Insider	Type	Value
Oct 27, 2025	Griffiths Richard	SELL	$0.00
Oct 27, 2025	Griffiths Richard	BUY	$0.00
Aug 3, 2025	Griffiths Richard	BUY	$0.00
Aug 3, 2025	Griffiths Richard	SELL	$0.00

3 institutional holders with $2.2M total value (366,940 shares) as of 2025-Q4. Top holders: MORGAN, TWO, BANK. Net selling activity: 2 institutions trimmed/exited vs 0 added.

Top Institutional Holders — 2025-Q4

#	Fund	Shares	Value	% of Tracked	Last Move
1	MORGAN STANLEY	324,630	$2.0M	88.5%	TRIM -73.1%
2	TWO SIGMA INVESTMENTS, LP	39,344	$239.2K	10.7%	TRIM -37.8%
3	BANK OF AMERICA CORP /DE/	2,966	$18.0K	0.8%	TRIM -30.7%

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
MORGAN STANLEY	TRIM	1,207,724	324,630	-73.1%	$2.0M	2025-Q4
TWO SIGMA INVESTMENTS, LP	TRIM	63,247	39,344	-37.8%	$239.2K	2025-Q4
UBS Group AG	ADD	228,509	307,363	+34.5%	$1.6M	2025-Q3
BANK OF AMERICA CORP /DE/	TRIM	5,095	3,531	-30.7%	$18.3K	2025-Q3
MORGAN STANLEY	TRIM	2,000,105	1,211,758	-39.4%	$7.0M	2025-Q2
UBS Group AG	TRIM	319,514	228,509	-28.5%	$1.3M	2025-Q2
BANK OF AMERICA CORP /DE/	NEAR_EXIT	64,886	5,095	-92.1%	$29.6K	2025-Q2
TWO SIGMA INVESTMENTS, LP	TRIM	142,052	76,008	-46.5%	$214.3K	2025-Q1
CITADEL ADVISORS LLC	NEAR_EXIT	288,237	66,341	-77.0%	$187.1K	2025-Q1
MORGAN STANLEY	DOUBLED	721,417	1,663,068	+130.5%	$11.4M	2024-Q4
UBS Group AG	DOUBLED	70,661	356,071	+403.9%	$2.4M	2024-Q4
CITADEL ADVISORS LLC	TRIM	438,997	288,237	-34.3%	$2.0M	2024-Q4
MORGAN STANLEY	DOUBLED	303,993	721,417	+137.3%	$13.1M	2024-Q3

1 unique insiders with 4 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

Date	Insider	Title	Type	Shares	Price	Value
Oct 27, 2025	Griffiths Richard Ian	10%+ Owner	SELL	2,000	$0.00	$0.00
Oct 27, 2025	Griffiths Richard Ian	10%+ Owner	BUY	2,000	$0.00	$0.00
Aug 3, 2025	Griffiths Richard Ian	10%+ Owner	BUY	20,000	$0.00	$0.00
Aug 3, 2025	Griffiths Richard Ian	10%+ Owner	SELL	20,000	$0.00	$0.00

1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 0 neutral. Avg impact: 6.0/10.

MIXED 8-K 6/10

Silence Therapeutics reported a significant year-over-year decline in revenue and increased net loss

Mar 5, 2026

∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Analyst Price Targets

$31.20 mean target +417.4% upside Strong Buy (1.83)

$4.00 Low $75.00 High

Metric	Value
Current Price	$6.03
Target Low	$4.00
Target Mean	$31.20
Target Median	$25.00
Target High	$75.00
# Analysts	5
Recommendation	Strong Buy (1.83)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$-0.11	$-0.11	$-0.11	80.0%	-10.0%	0↑ 1↓	$0.0B	523.2%	1
Next Q 2026-09-30	$-0.10	$-0.10	$-0.10	33.3%	+0.0%	1↑ 0↓	$0.0B	737.8%	1
Current FY 2026-12-31	$-0.40	$-0.40	$-0.40	78.4%	-2.6%	0↑ 1↓	$0.0B	580.9%	1
Next FY 2027-12-31	$-0.39	$-0.39	$-0.39	2.5%	+0.0%	1↑ 0↓	$0.0B	44.5%	1

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-0.110
7d ago	$-0.100	-0.010
30d ago	$-0.100	-0.010
60d ago	$-0.100	-0.010
90d ago	$-0.460	+0.350

1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
Mar 13, 2026	HC Wainwright & Co.	REITERATE	Buy	Buy

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 3, 2026

Clinical Trial

Study to Assess SLN124 in Patients With Polycythemia Vera

Phase Phase 2 — ACTIVE_NOT_RECRUITING

Jun 3, 2026

clinical_trial_readout

T-90d Trial Readout: SLN124 (Phase 2)

Trial: Study to Assess SLN124 in Patients With Polycythemia Vera Sponsor: Silence Therapeutics plc Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING Cond

Apr 24, 2026

short_interest

FTD: SLN — 78,743 shares ($0.6M) failed to deliver

Settlement: 20260424, Price: $7.84, FTD Value: $617,345.12, SILENCE THERAPEUTICS PLC SPONS